ADVAIR HFA Drug Patent Profile

When do Advair Hfa patents expire, and what generic alternatives are available?

Advair Hfa is a drug marketed by Glaxo Grp Ltd and is included in one NDA.

The generic ingredient in ADVAIR HFA is fluticasone propionate; salmeterol xinafoate. There are twenty-nine drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fluticasone propionate; salmeterol xinafoate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Advair Hfa

A generic version of ADVAIR HFA was approved as fluticasone propionate; salmeterol xinafoate by HIKMA on December 17^th, 2020.

Summary for ADVAIR HFA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	7
Clinical Trials:	84
Drug Prices:	Drug price information for ADVAIR HFA
Drug Sales Revenues:	Drug sales revenues for ADVAIR HFA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ADVAIR HFA
What excipients (inactive ingredients) are in ADVAIR HFA?	ADVAIR HFA excipients list
DailyMed Link:	ADVAIR HFA at DailyMed

See drug prices for ADVAIR HFA

See drug sales revenues for ADVAIR HFA

Recent Clinical Trials for ADVAIR HFA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
United States Department of Defense	Phase 1/Phase 2
University of Colorado, Denver	Phase 1/Phase 2
Becro Ltd.	Phase 3

See all ADVAIR HFA clinical trials

Pharmacology for ADVAIR HFA

Drug Class	Corticosteroid beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ADVAIR HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-002	Jun 8, 2006		RX	Yes	Yes
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006		RX	Yes	Yes

Expired US Patents for ADVAIR HFA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-003	Jun 8, 2006
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-002	Jun 8, 2006
Glaxo Grp Ltd	ADVAIR HFA	fluticasone propionate; salmeterol xinafoate	AEROSOL, METERED;INHALATION	021254-001	Jun 8, 2006

EU/EMA Drug Approvals for ADVAIR HFA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Teva B.V.	Airexar Spiromax	salmeterol xinafoate, fluticasone propionate	EMEA/H/C/004267Airexar Spiromax is indicated for use in adults aged 18 years and older only.AsthmaAirexar Spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.Chronic Obstructive Pulmonary Disease (COPD)Airexar Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1	Withdrawn	no	no	no	2016-08-18

International Patents for ADVAIR HFA

See the table below for patents covering ADVAIR HFA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	244199	PROCEDIMIENTO PARA PREPARAR DERIVADOS DE FENETANOLAMINA Y SUS SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES. (CHEMICAL COMPOUNDS)
Argentina	245687	UN PROCEDIMIENTO PARA LA PREPARACION DEL COMPUESTO 4-HIDROXI-ALFA(1) 6-4- (FENILBUTOXI)HEXIL-AMINO-METIL-1,3-BENCENEDIMETANOL (CHEMICAL COMPOUNDS)
Argentina	247721	UN PROCEDIMIENTO PARA LA PREPARACION DE COMPUESTOS DE FENETANOLAMINA Y SUS SALES Y SOLVATOS FARMACEUTICAMENTE ACEPTABLES (CHEMICAL COMPOUNDS)
Austria	390611

Supplementary Protection Certificates for ADVAIR HFA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0416951	C990012	Netherlands		PRODUCT NAME: SALMETEROL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN FLUTICASONPROPIONAAT,IN HET BIJZONDER SALMETEROLXINAFOAAT EN FLUTICASONPROPIONAAT; NATL REGISTRATION NO/DATE: RVG 23529 - RVG 23534 19990112; FIRST REGISTRATION: SE 14591 - 14596 19980907
0416951	12/1999	Austria		PRODUCT NAME: SALMETEROL, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, EINSCHLIESSLICH DES 1-HYDROXY-2-NAPHTHOATS (XINAFOAT) UND FLUTICASON PROPIONAT; NAT. REGISTRATION NO/DATE: 1-22897,1-22898, 1-22899,1-22900, 1-22901,1-22902 19990204; FIRST REGISTRATION: SE 14591-14596 19980907
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116

ADVAIR HFA market dynamics and financial trajectory (sales, loss of exclusivity, and competitive pressure)

Last updated: July 23, 2026

ADVAIR HFA (fluticasone propionate inhalation aerosol plus salmeterol) has shifted from an inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) blockbuster to a mature, share-contested respiratory product. The financial trajectory has been driven by (1) late-cycle erosion from generic fluticasone/salmeterol combination products, (2) replacement pressures from newer inhaler classes and preferred formularies, (3) retailer and payer contracting intensity, and (4) patent and exclusivity milestones that governed the timing of generic entry.

How has ADVAIR HFA performed financially over time?

Short answer: ADVAIR HFA is a mature brand with ongoing revenue decline as generic competitors expanded, while unit economics faced sustained price pressure through pharmacy channel contracting and payer preference changes.

What drives ADVAIR HFA revenue (volume, mix, pricing)?

Key revenue levers for an ICS/LABA aerosol brand:

• Net price vs list price: Heavy rebate and discount dynamics tied to formulary positioning.
• Channel inventory and category promotions: Respiratory categories often experience pull-through lags after supply changes or contract renegotiations.
• Mix within COPD and asthma: Shifts between asthma and COPD, and between guideline-preferred devices.
• Sustained substitution: When generic combination products are available, payers push switching and step therapy.

Where does ADVAIR HFA sit in the competitive ICS/LABA category?

ADVAIR HFA competes with:

• Other ICS/LABA molecules and devices (eg, fluticasone/salmeterol alternatives, budesonide/formoterol class products, and triple-therapy pathways that reduce ICS/LABA-only persistence).
• Fixed-dose combinations moving patients toward ICS/LABA plus LAMA triple therapy and newer inhaler delivery technologies.

Which companies sell generic or competing fluticasone/salmeterol combinations against ADVAIR HFA?

Short answer: The competitive set expands as generic fluticasone propionate/salmeterol inhalation aerosol products launch, with additional competitive pressure from branded ICS/LABA and device-differentiated alternatives.

What does the generic entry risk profile look like for combination aerosols?

For fixed-dose ICS/LABA aerosols, generic substitution accelerates once exclusivity barriers clear:

• Paragraph IV ANDA strategies are commonly used to force early entry where Orange Book-protected patents are challenged.
• Device and particle size considerations can affect perceived equivalence and patient acceptance, but payer contracting typically overrides practical barriers once approved products are available.

When does ADVAIR HFA lose exclusivity and face generic entry risk?

Short answer: ADVAIR HFA’s exclusivity timeline is late-cycle; generic entry is already reflected in current market dynamics and ongoing substitution.

What exclusivity and patent constructs govern inhaled combination brands?

For inhaled combination drugs, the entry timeline is shaped by:

• FDA patent listings in the Orange Book (composition, formulation, and device-related claims).
• Patent term adjustments and any qualifying regulatory exclusivity periods.
• Whether the listed patents are held to be infringed in Paragraph IV litigation, and settlement-triggered “launch dates.”

How do patent settlements change market outcomes?

When brand and generic reach settlement:

• Brand can obtain a delayed launch date for specific ANDA applicants.
• Generics not party to settlements can still launch earlier if they are cleared through litigation or have different patent carve-outs.

What patents protect ADVAIR HFA and how strong is the estate?

Short answer: ADVAIR HFA’s patent estate has been diluted by time and legal outcomes that enabled generic market access; remaining value depends on formulation or device-specific claims, if any, still listed and not expired.

Which patent types typically remain relevant late-cycle?

• Formulation/process patents tied to manufacturing consistency and aerosol performance.
• Method-of-use claims for asthma or COPD subsets, which are harder to design around.
• Device/propellant or particle engineering claims that can delay “true-to-brand” generics if asserted and litigated.

Does the patent estate impact payer contracting?

In practice:

• Even with residual patent lists, payers often switch aggressively once multiple generic equivalents are available.
• Litigation duration mainly affects specific ANDA timelines, not category-level substitution after generic proliferation.

What is the Orange Book status of ADVAIR HFA?

Short answer: ADVAIR HFA is represented in the FDA Orange Book under its approved application with associated listed patents; the current market environment indicates that generic equivalents have cleared the key remaining barriers.

How to read Orange Book listings for ADVAIR HFA (business use)

Orange Book status supports:

• Launch timing models for generic competitors.
• Risk mapping for ANDA Paragraph IV challenges.
• Identification of formulation or method-of-use patents that drive litigation strategy.

What generic entry risks exist for fluticasone/salmeterol combination aerosols like ADVAIR HFA?

Short answer: The primary launch risks are patent litigation outcomes, settlement terms, and ability to meet aerosol performance specifications that support interchangeability and uptake.

What barriers can still slow substitution even after approval?

• Formulary and step-therapy protocols that require documented switching steps.
• Patient adherence and inhaler technique issues tied to device differences.
• Rebate structures that lock in brand share or compensate pharmacies for preferred products.

How does ADVAIR HFA compare with newer respiratory products and triple-therapy shifts?

Short answer: Respiratory treatment trends reduce ICS/LABA-only duration by shifting patients toward triple therapy and device platforms perceived as easier or more effective.

What treatment guideline dynamics affect ADVAIR HFA persistence?

• Increased use of single-inhaler triple therapy reduces the addressable “ICS/LABA-only” segment.
• Preferred formulary placement for newer combinations can compress brand retention for established ICS/LABA products.

What FDA regulatory pathway dynamics shape market access for competitors?

Short answer: Generic competition is largely executed via ANDAs for inhaled combination products, while biologics are irrelevant to this small molecule aerosol.

What matters for ANDA approvals in inhaled aerosols?

• Bioequivalence for systemic exposure.
• Delivery performance and consistency, reflected in device and aerosol parameters.
• Labeling comparability, including asthma and COPD indications.

What litigation and settlement patterns typically impact ADVAIR HFA market timing?

Short answer: The market timing for generic ICS/LABA aerosol entry typically depends on Orange Book patent challenges and settlements that define delayed launch windows by applicant.

How business teams use litigation records

• Identify whether a launch is based on a full clearance or a specific settlement carve-out.
• Model switching rates based on number of ANDA entrants and rebate reactions.

How have pharmacy channel and payer contracts affected ADVAIR HFA performance?

Short answer: Broad generic availability usually drives:

• Lower net pricing
• Faster formulary switching
• Reduced channel willingness to stock or promote a brand once multiple generics exist.

What are the practical contracting effects?

• Wholesale and pharmacy stocking shifts as generic ASP spreads narrow and inventory turns accelerate.
• Payer utilization management intensifies to reduce branded spend.
• Copay dynamics can delay switching, but usually lose impact as generics gain share and brand copay support is reduced.

Market sizing and revenue exposure: where is the financial risk concentrated?

Short answer: Financial exposure is concentrated in:

• Asthma and COPD patient segments still using ICS/LABA aerosol regimens.
• Formularies where ADVAIR HFA historically maintained preferred status through contracting.
• Competitive sensitivity to COPD guideline updates and triple-therapy adoption.

What metrics best track trajectory?

• Monthly prescription volume and TRx share
• NDC-level net sales and ASP trends
• PBM formulary tier position changes
• Utilization management implementation rates

Key Takeaways

• ADVAIR HFA’s financial trajectory is consistent with a mature branded ICS/LABA aerosol that has faced sustained erosion from generic fluticasone/salmeterol combinations.
• Market dynamics are driven more by payer contracting, formulary switching, and category treatment evolution than by device-specific differentiation once multiple generics are available.
• The exclusivity and patent estate have already been largely consumed by time and generic entry, with the remaining impact focused on applicant-specific launch delays tied to Orange Book challenges and settlements.
• Revenue exposure concentrates in remaining ICS/LABA-only persistence pockets and payers that continue to resist full generic switching.

FAQs

1) What happens to ADVAIR HFA sales when a generic fluticasone/salmeterol aerosol enters the market?
Typically net sales decline as prescriptions shift to generics and payer tiers move to preferred generic status.

2) Do method-of-use patents for asthma or COPD delay generic entry for ADVAIR HFA?
They can, but practical delay depends on which specific patents are asserted, litigation outcomes, and whether settlement carve-outs apply.

3) How do triple-therapy guideline trends affect the addressable market for ADVAIR HFA?
They reduce duration on ICS/LABA-only regimens by shifting patients to single-inhaler triple therapy, compressing incremental market growth.

4) Which payer contract levers most influence continued ADVAIR HFA uptake after generic launch?
Formulary tiering, prior authorization criteria, step therapy enforcement, and rebate structures that affect pharmacy reimbursement.

5) What regulatory and manufacturing factors matter most for generics seeking uptake against ADVAIR HFA?
Bioequivalence compliance and aerosol performance consistency that supports confident switching and sustained utilization.

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Reports and labeling information for inhalation aerosol products. U.S. Food and Drug Administration.